Seminars in Arthritis and Rheumatism
Volume 40, Issue 1 , Pages 15-31 , August 2010

The Interface of Pain and Mood Disturbances in the Rheumatic Diseases

  • Don L. Goldenberg, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Don L. Goldenberg, MD, 2000 Washington St., Newton, MA 02468

References 

  1. Fitzcharles MA, Almahrezi A, Shir Y. Pain, understanding and challenges for the rheumatologist. Arthritis Rheum. 2005;52:3685–3692
  2. Lepine JP, Briley M. The epidemiology of pain in depression. Hum Psychopharmacol. 2004;19:3–7
  3. Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Sem Arthritis Rheum. 2007;36:339–356
  4. Croft P, Schollum J, Silman A. Population study of tender point counts and pain as evidence of fibromyalgia. BMJ. 1994;309:696–699
  5. Neumann L, Buskila D. Epidemiology of fibromyalgia. Curr Pain Headache Rep. 2003;7:362–368
  6. McBeth J, Jones K. Epidemiology of chronic musculoskeletal pain. Best Pract Res Clin Rheumatol. 2007;21:403–425
  7. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiolgy of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–3105
  8. McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain. 2004;111:77–83
  9. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163:2433–2445
  10. Aaron LA, Bradley LA, Alarcon GS, Alexander RW, Triana-Alexander M, Martin MY, et al. Psychiatric diagnoses in patients with fibromyalgia are related to health care-seeking behavior rather than to illness. Arthritis Rheum. 1996;39:436–445
  11. Kurland JE, Coyle WJ, Winkler A, Zable E. Prevalence of irritable bowel syndrome and depression in fibromyalgia. Dig Dis Sci. 2006;51:454–460
  12. Mertz HR. Irritable bowel syndrome. N Engl J Med. 2003;349:2136–2146
  13. Breslau N, Schultz LR, Stewart WF, Lipton RB, Lucia VC, Welch KM. Headache and major depression. Neurology. 2000;2:308–313
  14. Hagen K, Einarsen C, Zwart JA, Svebak S, Bovim G. The co-occurrence of headache and musculoskeletal symptoms amongst 51,050 adults in Norway. Headache. 2003;43:424
  15. Karpouzis KM, Spierings ELH. Circumstances of onset of chronic headache in patients attending a specialty practice. Headache. 1999;39:317–320
  16. Lenaerts ME, Gill PS. At the crossroads between tension-type headache and fibromyalgia. Curr Pain Headache Rep. 2006;10:463–466
  17. DeGood DE, Cundiff GW, Adams LE, Shutty MS. A psychosocial and behavioral comparison of reflex sympathetic dystrophy, low back pain, and headache patients. Pain. 1993;54:317–322
  18. Lapossy E, Maleitzke R, Hrycaj P, Mennet W, Muller W. The frequency of transition of chronic low back pain to fibromyalgia. Scand J Rheumatol. 1995;24:29–33
  19. Polatin PB, Kinney RK, Gatchel RJ, Lillo E, Mayer TG. Psychiatric illness and chronic low-back pain (The mind and the spine—which goes first?). Spine. 1993;18:66–71
  20. Goldenberg DL. Fibromyalgia syndrome a decade later: what have we learned?. Arch Intern Med. 1999;159:777–785
  21. Clauw DJ, Williams D, Lauerman W, Dahlman M, Aslami A, Nachemson AL, et al. Pain sensitivity as a correlate of clinical status in individuals with chronic low back pain. Spine. 1999;24:2035–2041
  22. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA. 2002;288:1775–1779
  23. Kim H, Neubert JK, San Miguel A, Xu K, Krishnaraju RK, Iadarola MJ, et al. Genetic influence on variability in human experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain. 2004;109:488–496
  24. Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I, et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet. 2005;14:135–143
  25. Diatchenko L, Nackley AG, Slade GD, Bhalang K, Belfer I, Max MB, et al. Catechol-O-methyltransferase gene poymorphisms are associated with multiple pain-evoking stimuli. Pain. 2006;125:216–224
  26. Suvinen TI, Reade PC, Kemppainen P, Kononen M, Dworkin SF. Review of aetiological concepts of temporomandibular pain disorders: towards a biopsychosocial model for integration of physical disorder factors with psychological and psychosocial impact factors. Eur J Pain. 2005;9:613–633
  27. Hudson JI, Hudson MS, Pliner LF, Goldenberg DL, Pope HG. Fibromyalgia and major affective disorder: a controlled phenomenology and family history study. Am J Psychiatry. 1985;142:441–446
  28. Arnold LM, Hudson JI, Hess EV, Ware AE, Fritz DA, Auchenbach MB, et al. Family study of fibromyalgia. Arthritis Rheum. 2004;50:944–952
  29. Hudson JI, Mangweth B, Pope HG, DeCol C, Hausmann A, Gutweniger S, et al. Family study of affective spectrum disorder. Arch Gen Psychiatry. 2003;60:170–177
  30. Akku AS, Senol A, Ayvacioglu NB, Tunc E, Eren I, Isler M. Is female predominance in irritable bowel syndrome related to fibromyalgia?. Rheumatol Int. 2004;24:106–109
  31. Caldarella MP, Giamberardino MA, Sacco F, Affaitati G, Milano A, Lerza R, et al. Sensitivity disturbances in patients with irritable bowel syndrome and fibromyalgia. Am J Gastroenterol. 2006;10:2782–2789
  32. Frissora CL, Koch KL. Symptom overlap and comorbidity of irritable bowel syndrome with other conditions. Curr Gastroenterol Rep. 2005;7:264–271
  33. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000;157:1552–1562
  34. Hariri AR, Drabant EM, Munoz KE, Kolachana BS, Mattay VS, Egan MF, et al. A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry. 2005;62:146–152
  35. Willeit M, Praschak-Rieder N, Neumeister A, Zill P, Leisch F, Stasny J, et al. A polymorphism (5-HTTLPR) in the serotonin transporter promoter gene is associated with DSM-IV depression subtypes in seasonal affective disorder. Mol Psychiatry. 2003;8:942–946
  36. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter poymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry. 2002;7:1115–1119
  37. Segman RH, Cooper-Kazaz R, Manniardi F, Goltser T, Halfon Y, Dobroborski T, et al. Association between the dopamine transporter gene and posttraumatic stress disorder. Mol Psychiatry. 2002;7:903–907
  38. Lee HJ, Lee MS, Kang RH, Kim H, Kim SD, Kee BS, et al. Influence of the serotonin transporter promoter gene polymorphism on susceptibility to posttraumatic stress disorder. Depress Anxiety. 2005;21:135–139
  39. Ramasubbu R, Tobias R, Buchan AM, Bech-Hansen NT. Serotonin transporter gene promoter region polymorphism associated with poststroke major depression. J Neuropsychiatry Clin Neurosci. 2006;18:96–99
  40. Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, et al. COMT val158 met genotype affects u-opioid neurotransmitter responses to a pain stressor. Science. 2003;299:1240–1243
  41. Buskila D, Sarzi-Puttini P. Biology and therapy of fibromyalgia (Genetic aspects of fibromyalgia syndrome). Arthritis Res Ther. 2006;8:218
  42. Offenbaecher M, Bondy B, deJonge S, Glatzeder K, Kruger M, Schoeps P, et al. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum. 1999;42:2482–2488
  43. Gursoy S, Erdal E, Herken H, Madenci E, AlaAehirli B, Erdal N. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int. 2003;23:104–107
  44. Kato K, Sullivan PF, Evengard B, Pedersen NL. Importance of genetic influences on chronic widespread pain. Arthritis Rheum. 2006;54:1682–1686
  45. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med. 2004;140:441–451
  46. Vogel C, Stallforth S, Sommer C. Altered pain behavior and regeneration after nerve injury in TNF receptor deficient mice. J Peripheral Nerv Sys. 2006;11:294–303
  47. Kleinschnitz C, Hofstetter HH, Meuth SG, Braeuninger S, Sommer C, Stoll G. T cell infiltration after chronic constriction injury of mouse sciatic nerve is associated with interleukin-17 expression. Exp Neurol. 2006;200:480–485
  48. Geber C, Fondel R, Kramer HH, Rolke R, Treede RD, Sommer C, et al. Psychophysics, flare, and neurosecretory function in human pain models: capsaicin versus electrically evoked pain. J Pain. 2007;8:503–514
  49. Beyreuther BK, Geis C, Stohr T, Sommer C. Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF. Neuropharmacology. 2007;52:1312–1317
  50. Warner-Scmidt JL, Duman RS. VGEF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA. 2007;104:4647–4652
  51. Laske C, Stransky E, Eschweiler GW, Klein R, Wittorf A, Leyhe T, et al. Increased BDNF serum concentration in fibromyalgia with or without depression or antidepressants. J Psychiatr Res. 2007;41:600–605
  52. Staud R. Biology and therapy of fibromyalgia: pain in fibromyalgia syndrome. Arth Res Ther. 2006;8:208
  53. Anisman H, Kokkinidis L, Merali Z. Further evidence for the depressive effects of cytokines: anhedonia and neurochemical changes. Brain Behav Immunity. 2002;16:544–546
  54. Uceyler N, Rogausch JP, Toyka KV, Sommer C. Differential expression of cytokines in painful and painless neuropathies. Neurology. 2007;69:42–49
  55. Uceyler N, Valenza R, Stock M, Schedel R, Sprotte G, Sommer C. Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain. Arthritis Rheum. 2006;54:2656–2664
  56. Wang H, Moser M, Schiltenwolf M, Buchner M. Circulating cytokine levels compared to pain in patients with fibromyalgia—a prospective longitudinal study over 6 months. J Rheumatol. 2008;35:1366–1370
  57. Dantzler R, Wollman E, Vitkovic L, Yirmiya R. Cytokines and depression: fortuitous or causative association?. Mol Psychiatry. 1999;4:328–332
  58. Kling MA, Alesci S, Csako G, Costello R, Luckenbaugh DA, Bonne O, et al. Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biol Psychiatry. 2007;62:309–313
  59. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology. 2001;40:743–749
  60. Ford DE, Erlinger TP. Depression and C-reactive protein in U.S. adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2004;164:1010–1014
  61. Elovainio M, Keltikangas-Jarvinen L, Pulkki-Raback L, Kivikmaki M, Puttonen S, Viikari L, et al. Depressive symptoms and C-reactive protein: the cardiovascular risk in Young Finns Study. Psychol Med. 2006;36:797–805
  62. Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein Muller B, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression. Mol Psychiatry. 2006;11:680–684
  63. Price DD. Psychological and neural mechanisms of the affective dimension of pain. Science. 2000;288:1769–1772
  64. Jones AK, Kulkarni B, Derbyshire SW. Pain mechanisms and their disorders. Br Med Bull. 2003;65:83–93
  65. Woolf CJ. Central sensitization: uncovering the relation between pain and plasticity. Anesthesiology. 2007;106(4):864–867
  66. Price DD, Staud R, Robinson ME, Mauderli AP, Cannon R, Vierck CJ. Enchanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain. 2002;99:49–59
  67. Price DD, Staud R. Neurobiology of fibromyalgia syndrome. J Rheumatol. 2005;75:22–28
  68. Staud R, Vierck CJ, Robinson ME, Price DD. Effects of the N-methyl-D-aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects. J Pain. 2005;6:323–332
  69. Staud R, Cannon RC. Temporal summation of pain from mechanical stimulation of muscle tissue in normal controls and subjects with fibromyalgia syndrome. Pain. 2003;102:87–95
  70. Price BH, Adams MA, Coyle JT. Neurology and psychiatry: closing the great divide. Neurology. 2000;54:8–14
  71. Sommer C. Is serotonin hyperalgesic or analgesic?. Curr Pain Headache Rep. 2006;10:101–106
  72. Zhao ZQ, Chiechio S, Sun Y-G, Zhang KH, Zhao CS, Scott M, et al. Mice lacking central serotonergic neurons show enhanced inflammatory pain and an impaired analgesic response to antidepressant drugs. J Neurosci. 2007;27:6045–6053
  73. Sergeyev V, Hokfelt T, Hurd Y. Serotonin and substance P coexist in dorsal raphe neurons of the human brain. NeuroReport. 1999;10:3967–3970
  74. Shirayama Y, Mitsushio H, Takashima M. Reduction of substance P after chronic antidepressant treatment in the striatum, substantia nigra and amydala of the rat. Brain Res. 2005;739:70–78
  75. Auer DP, Putz B, Kraft E, Lipinski B, Schill J, Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry. 2000;47:305–313
  76. Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2007;64:193–200
  77. Sarchielli P, Di Filippo M, Nardi K, Calabresi P. Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr Pain Headache Rep. 2007;11:343–351
  78. Harris RE, Sundgren PC, Pang Y, Hsu M, Petrou M, Kim SH, et al. Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fibromyalgia. Arthritis Rheum. 2008;58:903–907
  79. Nishiyori M, Ueda H. Prolonged gabepentin analgesia in an experimental mouse model of fibromyalgia. Mol Pain. 2008;6:52
  80. Drevets WC. Neuroplasticity in mood disorders. Dialogues Clin Neurosci. 2004;6:199–216
  81. Santarelli L, Gobbi G, Blier P, Hen R. Behavioral and physiologic effects of genetic or pharmacologic inactivation of the substance P receptor (NK1). J Clin Psychiatry. 2002;63(Suppl 11):11–17
  82. Wieseler-Frank J, Maier SF, Watkins LR. Immune to brain communication dynamically modulates pain: physiological and pathological consequences. Brain Behav Immun. 2005;19:104–111
  83. Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R. Neurotropin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res. 2005;136:29–37
  84. Chen B, Dowlatshahi D, MacQueeen GM. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry. 2001;50:260–265
  85. Bland ST, Tamlyn JP, Barrientos RM, Greenwood BN, Watkins LR, Campeau S, et al. Expression of fibroblast growth factor-2 and brain derived neurotrophic factor mRNA in the medial prefrontal cortex and hippocampus after uncontrollable or controllable stress. Neuroscience. 2007;144:1219–1228
  86. Scott DJ, Heitzeg MM, Koeppe RA, Stohler CS, Zubieta JK. Variations in the human pain stress experience mediated by ventral and dorsal basal ganglia dopamine activity. J Neurosci. 2006;26:10789–10795
  87. Magnusson JE, Martin RV. Additional evidence for the involvement of the basal ganglia in formalin-induced nociception: the role of the nucleus accumbens. Brain Res. 2002;942:128–132
  88. Altier N, Stewart J. The role of dopamine in the nucleus accumbens in analgesia. Life Sci. 1999;65:2269–2287
  89. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression. Br Med Bull. 2003;65:193–207
  90. Wood PB, Patterson JC, Sunderland JJ, Tainter KH, Glabus MF, Lilien DL. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study. J Pain. 1994;8:51–582007;8(1):51-8
  91. Kennedy SE, Koeppe RA, Young EA, Zubieta JK. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry. 2006;63:705–713
  92. Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci. 2007;27:1000–1006
  93. Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry. 2000;48:813–829
  94. Koeppe RA, Zubieta JK. Altered central mu-opioid receptor binding after psychological trauma. Biol Psychiatry. 2007;61:1030–1038
  95. Benedetti F, Mayberg HS, Wager TD, Stohler CS, Zubieta JK. Neurobiological mechanisms of the placebo effect. J Neurosci. 2005;25:10390–10402
  96. Milak MS, Parsey RV, Keilp J, Oguendo MA, Malone KM, Mann JJ. Neuroanatomic correlates of psychopathologic components of major depressive disorder. Arch Gen Psychiatry. 2005;62:397–408
  97. Vythilingam M, Heim C, Newport J, Miller AH, Anderson E, Bronen R, et al. Childhood trauma associated with smaller hippocampal volume in women with major depression. Am J Psychiatry. 2002;159(12):2072–2080
  98. Reagan LP, Rosell DR, Wood GE, Spedding M, Munoz C, Rothstein J, et al. Chronic resistant stress up-regulates GLT-1 mRNA and protein expression in the hippocampus of adult nonhuman primates. Proc Natl Acad Sci USA. 2004;101:2179–2184
  99. Taylor WD, MacFall JR, Meal P. Greater MRI lesion volume in elderly depressed subjects than in control subjects. Psychiatr Res. 2005;139:1–7
  100. Taylor WD, Steffens DC, Payne ME. Influence of serotonin transporter region polymorphisms on hippocampal volumes in late-life depression. Arch Gen Psychiatry. 2005;62:537–544
  101. Mobbs D, Petrovic P, Marchant JL, Hassabis D, Weiskopf N, Seymour B, et al. When fear is near: threat imminence elicits prefrontal-periaqueductal gray shifts in humans. Science. 2007;317:1079–1083
  102. Amodio DM, Frith CD. Meeting of minds: the medial frontal cortex and social cognition. Nat Rev Neurosci. 2006;7:268–277
  103. Kuchinad A, Schweinhardt P, Seminowicz DA, Wood PB, Chizh BA, Bushnell MC. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain?. J Neurosci. 2007;27:4004–4007
  104. Cook DB, Lange G, Ciccone DS, Liu WC, Steffener J, Natelson BH. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol. 2004;31:364–378
  105. Apkarian AV, Sosa Y, Sonty S, Levy RM, Harden RN, Parrish TB, et al. Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. J Neurosci. 2004;24:10410–10415
  106. Schmidt-Wilcke T, Leinisch E, Straube A, Kampfe N, Draganski NC, Diener HC, et al. Gray matter decrease in patients with chronic tension type headache. Neurology. 2005;65:1483–1486
  107. Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol. 2003;17:685–701
  108. Liotti M, Mayberg HS, McGinnis S, Brannan SL, Jerabek P. Unmasking disease-specific cerebral blood flow abnormalities: mood challenge in patients with remitted unipolar depression. Am J Psychiatry. 2002;159:1830–1840
  109. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002;46:1333–1343
  110. Giesecke T, Gracely RH, Williams DA, Geisser ME, Petzke FW, Clauw DJ. The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum. 2005;52:1577–1584
  111. Craig AD, Chen K, Bandy D, Reiman EM. Thermosensory activation of insular cortex. Nat Neurosci. 2000;3:184–190
  112. Emad Y, Ragab Y, Zeinhom F, El-Khouly G, Abou-Zeid A, Rasker J. Hippocampus dysfunction may explain symptoms of fibromyalgia syndrome (A study with single-voxel magnetic resonance spectroscopy). J Rheumatol. 2008;35:1371–1377
  113. Chang L, Berman S, Mayer EA, Suyenobu B, Derbyshire S, Naliboff B, et al. Brain responses to visceral and somatic stimuli in patients with irritable bowel syndrome with and without fibromyalgia. Am J Gastroenterol. 2003;98:1354–1361
  114. Price DD, Zhou Q, Moshiree B, Robinson ME, Verne GN. Peripheral and central contributions to hyperalgesia in irritable bowel syndrome. J Pain. 2006;7:529–535
  115. Iovino P, Tremolaterra F, Consalvo D, Sabbatini F, Mazzacca G, Ciacci C. Perception of electrocutaneous stimuli in irritable bowel syndrome. Am J Gastroenterol. 2006;101:596–603
  116. Cho HJ, Hotopf M, Wessely S. The placebo response in the treatment of chronic fatigue syndrome: a systematic review and meta-analysis. Psychosom Med. 2005;67:301–313
  117. Drossman DA. Irritable bowel syndrome and sexual/physical abuse history. Eur J Gastroenterol Hepatol. 1997;9:327–330
  118. Kellow JE, Langeluddecke PM, Eckersley GM, Jones MP, Tennant CC. Effects of acute psychologic stress on small-intestinal motility in health and the irritable bowel syndrome. Scand J Gastroenterol. 1992;27:53–58
  119. van Orshoven NP, Andriesse GI, van Schelven LJ, Smout AJ, Akkermans LM, Oey PL. Subtle involvement of the parasympathetic nervous system in patients with irritable bowel syndrome. Clin Autonomic Res. 2006;16:33–39
  120. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008;358:55–68
  121. Ruhe HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monamine depletion studies. Mol Psychiatry. 2007;12:331–359
  122. Ansorge MS, Zhou M, Lira A, Hen R, Gingrich JA. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science. 2004;306:879–881
  123. Khasar SG, Burkham J, Dina OA, Brown AS, Bogen O, Alessandri-Haber N, et al. Stress induces a switch of intracellular signaling in sensory neurons in a model of generalized pain. J Neurosci. 2008;28:5721–5730
  124. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev. 2007;87:873–904
  125. Kajantie E, Phillips DI. The effects of sex and hormonal status on the physiological response to acute psychosocial stress. Psychoneuroendocrinology. 2006;31(2):151–178
  126. Ehlert U, Gaab J, Heinrichs M. Psychoneuroendocrinological contributions to the etiology of depression, posttraumatic stress disorder, and stress related bodily disorders: the role of the hypothalmus-pituitary-adrenal axis. Biol Psychol. 2001;57:141–152
  127. Amital D, Fostick L, Polliack ML, Segev S, Zohar J, Rubinow A, et al. Posttraumatic stress disorder, tenderness, and fibromyalgia syndrome: are they different entities?. J Psychosom Res. 2006;61:663–669
  128. Arnson Y, Amital D, Fostick L, Silberman A, Polliack ML, Zohar J, et al. Physical activity protects male patients with post-traumatic stress disorder from developing severe fibromyalgia. Clin Exp Rheumatol. 2007;25:529–533
  129. Davis M, Zautra AJ, Reich J. Vulnerability to stress among women in chronic pain from fibromyalgia and osteoarthritis. Ann Behav Med. 2001;23:215–226
  130. Gursel Y, Ergin S, Ulus Y, Erdogan MF, Yalcin P, Evcik D. Hormonal responses to exercise stress test in patients with fibromyalgia syndrome. Clin Rheumatol. 2001;20:401–405
  131. Okifuji A, Turk DC. Stress and psychophysiological dysregulation in patients with fibromyalgia syndrome. Appl Psychophysiol Biofeedback. 2002;27:129–141
  132. Wood PB. Stress and dopamine: implications for the pathophysiology of chronic widespread pain. Med Hypotheses. 2004;62:420–424
  133. Merali Z, Du L, Hrdina P, Palkovits M, Faludi G, Poulter MO, et al. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA (A) receptor subunits in frontal cortical brain regions. J Neurosci. 2004;24:1478–1485
  134. Carroll BJ, Cassidy F, Naftlowitz D, Tatham NE, Wilson WH, Iranmanesh A, et al. Pathophysiology of hypercorticolism in depression. Acta Psychiatr Scand. 2007;433:90–103
  135. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharm. 2000;23:477–501
  136. Nicolson NA. Childhood parental loss and cortisol levels in adult men. Psychoneuroendocrinology. 2004;29:1012–1018
  137. Heim C, Ehlert U, Hellhammer DH. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. Psychoneuroendocrinology. 2000;25:1–35
  138. Boyle MP, Brewer JA, Funatsu M, Wozniak DF, Tsien JZ, Izumi Y, et al. Acquired deficit of forebrain glucocorticoid receptor produces depression-like changes in adrenal axis regulation and behavior. Proc Natl Acad Sci USA. 2005;102:473–478
  139. Heim C, Newport DJ, Bonsall R, Miller AH, Nemeroff CB. Altered pituitary-adrenal axis responses to provocative challenge tests in adult survivors of childhood abuse. Am J Psychiatry. 2001;158:575–581
  140. Lee R, Geracioti TD, Kasckow JW, Coccaro EF. Childhood trauma and personality disorder: positive correlation with adult CSF corticotropin-releasing factor concentrations. Am J Psychiatry. 2005;162:995–997
  141. McLean SA, Williams DA, Harris RE, Kop WJ, Groner KH, Ambrose K, et al. Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgia. Arthritis Rheum. 2005;52:3660–3669
  142. Crofford LJ. Neuroendocrine abnormalities in fibromyalgia and related disorders. Am J Med Sci. 1998;315:359–366
  143. Clauw DJ, Chrousos GP. Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation. 1997;4:134–153
  144. Williams DA, Graceley RH. Biology and therapy of fibromyalgia. Arthritis Res Ther. 2006;8:224–236
  145. McBeth J, Macfarlane GJ, Hunt IM, Silman A. Risk factors for persistent chronic widespread pain: a community-based study. Rheumatology. 2001;40:95–101
  146. McBeth J, Macfarlane GJ, Benjamin S, Silman AJ. Features of somatization predict the onset of chronic widespread pain: results of a large population-based study. Arthritis Rheum. 2001;44:940–946
  147. Hudson JI, Pope HG. Does childhood sexual abuse cause fibromyalgia?. Arthritis Rheum. 1995;38:161–163
  148. Heim C, Wagner D, Maloney E, Papanicolaou DA, Solomon L, Jones JF, et al. Early adverse experience and risk for chronic fatigue syndrome: results from a population-based study. Arch Gen Psychiatry. 2006;63:1258–1266
  149. McLean SA, Clauw DJ, Abelson JL, Liberzon I. The development of persistent pain and psychological morbidity after motor vehicle collision: integrating the potential role of stress response systems into a biopsychosocial model. Psychosom Med. 2005;67:783–790
  150. Arguelles LM, Afari N, Buchwald DS, Clauw DJ, Furner S, Goldberg J. A twin study of posttraumatic stress disorder symptoms and chronic widespread pain. Pain. 2006;124:150–157
  151. Jones GT, Silman AJ, Macfarlane G. J Predicting the onset of widespread body pain among children. Arthritis Rheum. 2003;48:2615–2621
  152. Gur A, Karakoc M, Nas K, Cevik R, Denli A, Sarac J. Cytokines and depression in cases with fibromyalgia. J Rheumatol. 2002;29:358–361
  153. Adler GK, Kinsley BT, Hurwitz S, Mossey CJ, Goldenberg DL. Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Am J Med. 1999;106:534–543
  154. McLean SA, Williams DA, Stein PK, Harris RE, Lyden AK, Whalen G, et al. Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. Neuropsychopharmacology. 2006;31:2776–2782
  155. McBeth J, Silman AJ, Gupta A, Chiu YH, Ray D, Morriss R, et al. Moderation of psychosocial risk factors through dysfunction of the hypothalamic-pituitary-adrenal axis in the onset of chronic widespread musculoskeletal pain. Arthritis Rheum. 2007;56:360–371
  156. Martinez-Lavin M, Hermosillo AG. Autonomic nervous system dysfunction may explain the multisystem features of fibromyalgia. Semin Arthritis Rheum. 2000;29:197–199
  157. Chiu YH, Silman AJ, Macfarlane GJ, Ray D, Gupta A, Dickens C, et al. Poor sleep and depression are independently associated with a reduced pain threshold. Pain. 2005;115:316–321
  158. Drewes AM. Pain and sleep disturbances with special reference to fibromyalgia and rheumatoid arthritis. Rheumatology. 1999;38:1035–1038
  159. Naughton F, Ashworth P, Skevington S. Does sleep quality predict pain-related disability in chronic pain patients? (The mediating role of depression and pain severity). Pain. 2007;127:243–252
  160. Smith MT, Haythornthwaite JA. How do sleep disturbance and chronic pain inter-relate? (Insights from the longitudinal and cognitive-behavioral clinical trials literature). Sleep Med Rev. 2004;8:119–132
  161. Stein PK, Domitrivich PP, Ambrose K, Lyden A, Fine M, Gracely RH, et al. Sex effects on heart rate variability in fibromyalgia and Gulf War illness. Arthritis Rheum. 2004;51:700–708
  162. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006;367:1618–1625
  163. Keogh E, McCracken LM, Eccleston C. Gender moderates the association between depression and disability in chronic pain patients. Eur J Pain. 2006;10:413–422
  164. Fillingham RB. Individual differences in pain responses. Curr Rheumatol Rep. 2005;7:342–347
  165. Kuba T, Quinones-Jenab V. The role of female gonadal hormones in behavioral sex differences in persistent and chronic pain: clinical versus preclinical studies. Brain Res Bull. 2005;66:179–188
  166. Sheehy C. Depression in rheumatoid arthritis. Rheumatology. 2006;45:1325–1327
  167. Dickens C, McGowan L, Clark-Carter D. Depression in rheumatoid arthritis. Psychol Med. 2008;64:52–60
  168. Lowe B, Willand L, Eich W. Psychiatric comorbidity and work disability in patients with inflammatory rheumatic disease. Psychosom Med. 2007;66:395–402
  169. Abdel-Nasser AM, Abdel-Azim S, El-Badawy SA, Rasker JJ, Valkenburg HA. Depression and depressive symptoms in rheumatoid arthritis patients: an analysis of their occurrence and determinants. Br J Rheumatol. 1998;37:391–397
  170. Frank RG, Back NC, Parker JC, Kashani JH, Elliott TR, Haut AE, et al. Depression in rheumatoid arthritis. J Rheumatol. 1988;15:920–925
  171. Ang DC, Choi H, Kroenke K, Wolfe F. Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. J Rheumatol. 2005;32:1013–1019
  172. Parker JC, Wright GE. The implications of depression for pain and disability in rheumatoid arthritis. Arthritis Care Res. 1995;8:279–283
  173. McFarlane AC, Brooks PM. An analysis of the relationship between psychological morbidity and disease activity in rheumatoid arthritis. J Rheumatol. 1988;15:926–930
  174. Jones AKP, Cunningham VJ, Ha-Kawa S, Fujiwara T, Luthra SK, Jones T. Changes in central opiod receptor binding in relation to inflammation and pain in patients with rheumatoid arthritis. Br J Rheumatol. 1994;33:309–316
  175. Jones AKP, Derbyshire SWG. Cerebral mechanisms operating in the presence and absence of inflammatory pain. Ann Rheum Dis. 1996;55:411–420
  176. Rosemann T, Backenstrass M, Joest K, Rosemann A, Szecsenyi J, Laux G. Predictors of depression in a sample of 1,021 primary care patients with osteoarthritis. Arthritis Rheum. 2007;57:415–422
  177. Sale JE, Gignac M, Hawker G, Sale JEM, Gignac M, Hawker G. The relationship between disease symptoms, life events, coping and treatment, and depression among older adults with osteoarthritis. J Rheumatol. 2008;35:335–342
  178. Machado GP, Gignac MA, Badley EM, Machado GPM, Gignac MAM, Badley EM. Participation restrictions among older adults with osteoarthritis: a mediated model of physical symptoms, activity limitations, and depression. Arthritis Rheum. 2008;59:129–135
  179. Kulkarni B, Bentley DE, Elliott R, Julyan PJ, Boger E, Watson A, et al. Arthritic pain is processed in brain areas concerned with emotions and fear. Arthritis Rheum. 2007;56:1345–1354
  180. Fiorentino PM, Tallents RH, Miller J-N, Brouxhon SM, O'Banion MK, Puzas JE, et al. Spinal interleukin-1B in a mouse model of arthritis and joint pain. Arthritis Rheum. 2008;58:3100–3109
  181. Inglis JJ, McNamee KE, Chia S-L, Essex D, Feldman M, Williams RO, et al. Regulation of pain sensitivity in experimental osteoarthritis by the endogenous opioid system. Arthritis Rheum. 2008;58:3110–3119
  182. Farrell M, Gibson S, McMeeken J, Helme R. Pain mechanisms in osteoarthritis of the hands. J Rheumatol. 2000;27:441–447
  183. Bajaj P, Graven-Nilsen T, Arendt-Nielsen L. Osteoarthritis and its association with muscle hyperalgesia: an experimental controlled study. Pain. 2001;93:107–114
  184. Imamura M, Tomikawa Imamura S, Kaziyama HHS, Targino RA, Hsing WT, Marques De Souza LP, et al. Impact of nervous system hyperalgesia on pain, disability and quality of life in patients with knee osteoarthritis: a controlled study. Arthritis Care Res. 2008;59:1424–1431
  185. Zautra AJ, Smith BW. Depression and reactivity to stress in older women with rheumatoid arthritis and osteoarthritis. Psychosom Med. 2001;63:687–696
  186. Zautra AJ, Fasman R, Parish BP, Davis MC. Daily fatigue in women with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Pain. 2007;128:128–135
  187. Li X, Gignac MA, Anis AH, Li X, Gignac MAM, Anis AH. Workplace, psychosocial factors, and depressive symptoms among working people with arthritis: a longitudinal study. J Rheumatol. 2006;33:1849–1855
  188. Menefee LA, Cohen MJ, Anderson WR, Doghramji K, Frank ED, Lee H. Sleep disturbance and nonmalignant chronic pain: a comprehensive review of the literature. Pain Med. 2000;1:156–172
  189. Nicassio PM, Moxham EG, Schuman CE, Gevirtz RN. The contribution of pain, reported sleep quality, and depressive symptoms to fatigue in fibromyalgia. Pain. 2002;100:271–279
  190. Schneider-Helmert D, Whitehouse II, Kumar A, Lijzenga C. Insomnia and alpha sleep in chronic non-organic pain as compared to primary insomnia. Neuropsychobiology. 2001;43:54–58
  191. Hirsch M, Carlander B, Vergé M, Tafti M, Anaya J-M, Billiard M, et al. Objective and subjective sleep disturbances in patients with rheumatoid arthritis: a reappraisal. Arthritis Rheum. 1994;37:41–49
  192. Kupfer DJ, Foster FG, Coble P, McPartland RJ, Ulrich RF. The application of EEG sleep for the differential diagnosis of affective disorders. Am J Psychiatry. 1978;135:69–74
  193. Affleck G, Urrows S, Tennen H, Higgins P, Abeles M. Sequential daily relations of sleep, pain intensity, and attention to pain among women with fibromyalgia. Pain. 1996;68:363–368
  194. Branco J, Atalaia A, Paiva T. Sleep cycles and alpha-delta sleep in fibromyalgia syndrome. J Rheumatol. 1994;21:1113–1117
  195. Chokroverty S. Diagnosis and treatment of sleep disorders caused by co-morbid disease. Neurology. 2000;54:S8–S15
  196. Bunney WE, Bunney BG. Molecular clock genes in man and lower animals: possible implications for circadian abnormalities in depression. Neuropsychopharmacology. 2000;22:335–345
  197. Finset A, Horven Wigers S, Gotestam KG. Depressed mood impedes pain treatment response in patients with fibromyalgia. J Rheumatol. 2004;31:976–980
  198. Lin E, Katon W, von Korff M. Effect of improving depression care on pain and functional outcomes among older adults with arthritis: a randomized controlled trial. JAMA. 2003;290:2428–2434
  199. Butler SH, Weil-Fugazza J, Godedroy F, Besson JM. Reduction of arthritis and pain behaviour following chronic administration of amitriptyline or imipramine in rats with adjuvant-induced arthritis. Pain. 1985;23:159–175
  200. Bird H, Broggini M. Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study. J Rheumatol. 2000;27:2791–2797
  201. Arnold LM, Keck PE. Antidepressant treatment of fibromyalgia (A meta-analysis and review). Psychosomatics. 2001;41:104–113
  202. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119:5–15
  203. Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005;32:1975–1985
  204. Butler SH, Weil-Fugazza J, Godefroy F, Besson J-M. Reduction of arthritis and pain behaviour following chronic administration of amitriptyline or imipramine in rats with adjuvant-induced arthritis. Pain. 1985;23:159–175
  205. Gerner P, Mujtaba M, Sinnott CJ, Wang GK. Amitriptyline versus bupivacaine in rat sciatic nerve blockade. Anesthesiology. 2001;94:661–667
  206. Duric V, McCarson KE. Effects of analgesic or antidepressant drugs on pain or stress-evoked hippocampal and spinal neurokinin-1 receptor and brain-derived neurotrophic gene expression in the rat. J Pharmacol Exp Ther. 2006;319:1235–1243
  207. Pheasant H, Bursk A, Goldfarb J, Azen SP, Weiss JN, Borelli L. Amitriptyline and chronic low-back pain (A randomized double-blind crossover study). Spine. 1983;8:552–557
  208. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum. 1986;29:1371–1377
  209. Bennett RM. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia: an analysis of outcome measures. Curr Rheumatol Rep. 2002;4:286–292
  210. Alcoff J, Jones E, Rust R. Controlled trial of imipramine for chronic low back pain. J Family Prac. 1982;14:841–846
  211. Ward N, Bokan JA, Phillips M, Benedetti C, Butler S, Spengler D. Antidepressants in concomitant chronic back pain and depression: doxepin and desipramine compared. J Clin Psychiatry. 1984;45:54–59
  212. O'Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Family Prac. 1999;48:980–990
  213. Bomholt SF, Mikkelsen JD, Blackburn-Munro G. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology. 2005;48:252–263
  214. Mochizucki D. Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol. 2004;19(Suppl):S15–S19
  215. Goldenberg DL, Mayskiy M, Mossey CJ, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996;39:1852–1859
  216. Jones CK, Peters SC, Shannon HE. Synergistc interactions between the dual serotonergic, noradrenergic reuptake inhibitor duloxetine and the non-steroidal anti-inflammatory drug ibuprofen in inflammatory pain in rodents. Eur J Pain. 2008;11:208–215
  217. Sarzi-Puttini P, Buskila D, Carrabba M, Doria A, Atzeni F. Treatment strategy in fibromyalgia syndrome: where are we now?. Semin Arthritis Rheum. 2008;37:353–365
  218. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264–1273
  219. Arnold LM, Goldenberg DL, Stanford SB, Lalonde JK, Sandhu HS, Keck PE, et al. Gabapentin in the treatment of fibromyalgia. Arthritis Rheum. 2007;56:1336–1344
  220. Crofford LJ. The relationship of fibromyalgia to neuropathic pain syndromes. J Rheumatol. 2005;Jul 20;(3):CD 005452. Review
  221. Wiffen PJ, McQuay HJ, Edwards JE, Moore RA. Gabepentin for acute and chronic pain. Cochrane Database Syst Rev. 2005;3:5452–5456
  222. Weber MM, Emrich HM. Current and historical concepts of opiate treatment in psychiatric disorders. Int Clin Psychopharmacol. 1998;3:255–266
  223. Walker JS. Anti-inflammatory effects of opioids. Adv Exp Med Biol. 2003;521:148–150
  224. Langford R, McKenna F, Ratcliffe S, Vojtassak J, Richarz U. Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial. Arthritis Rheum. 2007;56:1829–1837
  225. Russell IJ, Kamin M, Bennett RM, Schnitzer TJ, Green JA, Katz WA. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol. 2000;6:250–257
  226. Vorsanger G, Xiang J, Jordan D, Farrell J. Post hoc analysis of a randomized, double-blind, placebo-controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clin Ther. 2007;29:2520–2535
  227. Croft P, Burt J, Schollum J, Thomas E, Macfarlane G, Silman A. More pain, more tender points: is fibromyalgia just one end of a continuous spectrum?. Ann Rheum Dis. 1996;55:482–485
  228. Suulivan MJ, Martel MO, Tripp D, Savard A, Crombez G. The relation between catastrophizing and the communication of pain experience. Pain. 2006;122:282–288
  229. Sullivan MJ, Thorn B, Haythornthwaite JA, Keefe F, Martin M, Bradley LA, et al. Theoretical perspectives on the relation between catastrophizing and pain. Clin J Pain. 2001;17:52–64
  230. Parker JC, Smarr KL, Buckelew SP, Stucky-Ropp RC, Hewett JE, Johnson JC, et al. Effects of stress management on clinical outcomes in rheumatoid arthritis. Arthritis Rheum. 1995;38:1807–1818
  231. Edwards RR, Bingham CO, Bathon J, Haythornthwaite JA. Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases. Arthritis Rheum. 2006;55:325–332
  232. Gracely RH, Geisser M, Giesecke T, Grant MA, Petzke F, Williams DA, et al. Pain catastrophising and neural responses to pain among persons with fibromyalgia. Brain. 2004;127:835–843
  233. Sullivan MJ, Adams H, Tripp D, Stanish WD, Sullivan MJL, Adams H, et al. Stage of chronicity and treatment response in patients with musculoskeletal injuries and concurrent symptoms of depression. Pain. 2008;135:151–159
  234. DeRubeis RJ, Gelfand LA, Tand TZ, Simons AD. Medications versus cognitive behavior therapy for severely depressed outpatients: meta-analysis of four randomized comparisons. Am J Psychiatry. 1999;156:1007–1013
  235. Goldapple K, Segal Z, Garson C. Modulation of cortical-limbic pathways in major depression: treatment specific effects of cognitive behavior therapy. Arch Gen Psychiatry. 2004;61:34–41
  236. Buckelew SP, Conway R, Parker J, Deuser WE, Read J, Witty TE, et al. Biofeedback/relaxation training and exercise interventions for fibromyalgia: a prospective trial. Arthritis Care Res. 1998;11:196–209
  237. Williams DA, Cary MA, Groner KH, Chaplin W, Glazer LJ, Rodriquez AM, et al. Improving physical functional status in patients with fibromyalgia: a brief cognitive behavioral intervention. J Rheumatol. 2002;29:1280–1286
  238. Bradley LA, Alberts KA. Psychological and behavioral approaches to pain management for patients with rheumatic disease. Rheum Dis Clin North Am. 1999;25:215–232
  239. Nabkasorn C, Miyai N, Sootmongkol A, Junprasert S, Yamamoto H, Arita M, et al. Effects of physical exercise on depression, neuroendocrine stress hormones and physiological fitness in adolescent females with depressive symptoms. Eur J Public Health. 2006;16:179–184
  240. Minor MA, Hewitt JE, Webel RR, Anderson SK, Kay DR. Efficacy of physical conditioning exercise in patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 1989;32:1396–1405
  241. Yocum DE, Castro WL, Cornett M. Exercise, education, and behavioral modification as alternative therapy for pain and stress in rheumatic disease. Rheum Dis Clin North Am. 2000;26:146–156
  242. Busch A, Schachter CL, Overend TJ, Peloso PM, Barber KA. Exercise for fibromyalgia: a systemic review. J Rheumatol. 2008;35:1130–1144
  243. Gowans SE, de Hueck A. Effectiveness of exercise in management of fibromyalgia. Curr Opin Rheumatol. 2004;16:138–142
  244. Mannerkorpi K, Iversen MD. Physical exercise in fibromyalgia and related syndromes. Best Pract Res Clin Rheumatol. 2003;17:629–647
  245. Neuberger GB, Aaronson LS, Gajewski B, Embretson SE, Cagle PE, Loudon JK, et al. Predictors of exercise and effects of exercise on symptoms, function, aerobic fitness and disease outcomes of rheumatoid arthritis. Arthritis Rheum. 2007;57:943–952
  246. Giesecke T, Williams DA, Harris RE, Cupps TR, Tian X, Tian TX, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum. 2003;48:2916–2922
  247. Guedj E, Taieb D, Cammilleri S, Lussato D, de LC, Niboyet J, et al. (99m)Tc-ECD brain perfusion SPECT in hyperalgesic fibromyalgia. Eur J Nucl Med Mol Imaging. 2007;34:130–134
  248. Walitt B, Roebeck-Spencer T, Esposito G, Atkins F, Bleiberg J, Foster G, et al. The effects of multidisciplinary therapy on positron emission tomography of the brain in fibromyalgia: a pilot study. Rheumatol Int. 2007;27:1019–1024
  249. Bonifazi M, Lisa SA, Cambiaggi C, Felici A, Grasso G, Lodi L, et al. Changes in salivary cortisol and corticosteroid receptor-alpha mRNA expression following a 3-week multidisciplinary treatment program in patients with fibromyalgia. Psychoneuroendocrinology. 2006;31:1075–1086
  250. Blier P, Gobbi G, Haddjeri N, Santarelli L, Mathew G, Hen R. Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response. J Psychiatry Neurosci. 2004;29:208–218
  251. Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology. 2006;31:628–636
  252. Graven-Nielsen T, Henriksson KG, Johnson A, Gerdle B, Arendt-Nielsen L. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain. 2000;85:483–491
  253. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856–864
  254. Malemud CJ, Miller AH. Pro-inflammatory cytokine-induced SAPK/MAPK and JAK/STAT in rheumatoid arthritis and the new antidepressant drugs. Exp Opin Therap Targets. 2008;12:171–183
  255. Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45:651–660
  256. Hsu MC, Clauw DJ. A different type of procedure for a different type of pain. Arthritis Rheum. 2006;54:3725–3727
  257. Fregni F, Gimenes R, Valle AC, Ferreira MJ, Rocha RR, Natalle L, et al. A randomized, sham-controlled, proof of principle study of transcranial direct current stimulation for the treatment of pain in fibromyalgia. Arthritis Rheum. 2006;54:3988–3998
  258. Usui C, Doi N, Nishioka M, Komatsu H, Yamamoto R, Ohkubo T, et al. Electroconvulsive therapy improves severe pain associated with fibromyalgia. Pain. 2006;121:276–280

 Dr. Goldenberg is a consultant and on the Advisory Board for Pfizer, Lilly, and Forest Pharmaceuticals.

PII: S0049-0172(08)00213-8

doi: 10.1016/j.semarthrit.2008.11.005

Seminars in Arthritis and Rheumatism
Volume 40, Issue 1 , Pages 15-31 , August 2010

Article Tools